MCID: HRY003
MIFTS: 59

Hairy Cell Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Hairy Cell Leukemia

MalaCards integrated aliases for Hairy Cell Leukemia:

Name: Hairy Cell Leukemia 12 76 53 29 15 73
Hairy Cell Leukemia Variant 12 59 73
Hcl-V 12 59 15
Prolymphocytic Variant of Hairy Cell Leukemia 59
Leukemic Reticuloendotheliosis Variant 59
Leukemic Reticuloendotheliosis 53
Prolymphocytic Variant of Hcl 59
Hairy Cell Leukaemia Variant 12
Leukemia, Hairy Cell 44
Hairy-Cell Leukemia 37
Leukemia Hairy Cell 55
Hcl 53

Characteristics:

Orphanet epidemiological data:

59
hairy cell leukemia variant
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (United States); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:285 DOID:713
ICD10 33 C91.4 C91.40
ICD9CM 35 202.4
MeSH 44 D007943
NCIt 50 C7402 C7401
Orphanet 59 ORPHA300878
UMLS via Orphanet 74 C0349633
ICD10 via Orphanet 34 C91.4
KEGG 37 H00006

Summaries for Hairy Cell Leukemia

NIH Rare Diseases : 53 Hairy cell leukemia is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. The condition is named after these excess B cells which look 'hairy' under a microscope. As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced.   The symptoms include a large spleen (splenomegalia) but without an increase of lymph nodes, and general symptoms such as fever, night sweats, fatigue, weight loss. Blood exams show the decreased number of blood cells and platelets. The diagnosis can be made with the biopsy of the bone marrow, blood exams showing antigens that are released by the B-cells. The leukemia cells show an specific change (variation or mutation) in a gene involved in cell growth, the BRAF gene, that increases the growth and spread of cancer cells. The decision to treat depends in whether or not symptoms, splenomegaly, or other complications are present. About 10% of all patients will never require treatment. The cause is still unknown. While there is no cure, treatment can lead to remission which can last for years.  

MalaCards based summary : Hairy Cell Leukemia, also known as hairy cell leukemia variant, is related to refractory hairy cell leukemia and sezary's disease. An important gene associated with Hairy Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Innate Immune System. The drugs Doxil and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by over production of B cells (lymphocytes) by the bone marrow where the B cells appear hairy under a microscope.

Wikipedia : 76 Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal... more...

Related Diseases for Hairy Cell Leukemia

Diseases related to Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 refractory hairy cell leukemia 34.0 BRAF CD22
2 sezary's disease 30.1 IFNA1 IL2 IL2RA
3 cutaneous t cell lymphoma 30.0 IFNA1 IL2 IL2RA
4 prolymphocytic leukemia 30.0 ADA CCND1 CD5
5 cryoglobulinemia, familial mixed 29.8 CD5 IFNA1 IFNA2
6 essential thrombocythemia 29.8 IFNA1 IFNA2 IL3
7 mantle cell lymphoma 29.4 CCND1 CD5 ITGAX
8 cll/sll 29.4 CCND1 CD5
9 mycosis fungoides 29.0 IFNA1 IFNA2 IL2 IL2RA ITGAE
10 leukemia, chronic lymphocytic 28.8 ACP5 BRAF CCND1 CD5 IL2 IL2RA
11 lymphoma, non-hodgkin, familial 26.3 BRAF CCND1 CD22 CD5 IL2 IL2RA
12 classic hairy cell leukemia 12.3
13 intrapelvic lymph node leukemic reticuloendotheliosis 12.3
14 splenic manifestation of hairy cell leukemia 12.2
15 leukemia 11.2
16 gastrinoma 11.1
17 macs syndrome 11.1
18 richter's syndrome 11.1
19 lymphomatoid granulomatosis 10.7 IFNA1 IFNA2
20 squamous papillomatosis 10.7 IFNA1 IFNA2
21 tuberculous empyema 10.6 ADA IL2
22 recurrent respiratory papillomatosis 10.6 IFNA2 IL2
23 lymphoma 10.5
24 leukemia, chronic lymphocytic 2 10.4
25 leukemia, b-cell, chronic 10.4
26 atopic keratoconjunctivitis 10.4 IL2 IL3
27 extramedullary plasmacytoma 10.3 CCND1 IL2
28 viral infectious disease 10.3 IFNA1 IFNA2 IL2
29 leukocyte disease 10.3 IFNA1 IL2 IL3
30 combined immunodeficiency, x-linked 10.3 ADA IL2 IL2RA
31 autoimmune lymphoproliferative syndrome, type v 10.2
32 b-cell lymphomas 10.2
33 cervicitis 10.2 IL2 IL2RA
34 immune deficiency disease 10.2 ADA IL2 IL2RA
35 bladder lymphoma 10.2 CD5 ITGAX
36 myeloid leukemia 10.2
37 discoid lupus erythematosus 10.2 IFNA1 IFNA2
38 vasculitis 10.1
39 hypereosinophilic syndrome 10.1 IFNA1 IL2RA IL3
40 polycythemia vera 10.1
41 leukemia, acute myeloid 10.1
42 sarcoma 10.1
43 polycythemia 10.1
44 splenomegaly 10.1
45 bone marrow cancer 10.1 IFNA1 IFNA2 IL3
46 b cell prolymphocytic leukemia 10.1 CD5 IL2RA
47 diphtheria 10.1 IL2 IL2RA IL3
48 lymphoma, hodgkin, classic 10.0
49 myelofibrosis 10.0
50 non-secretory myeloma 10.0 ITGAE ITGAX

Graphical network of the top 20 diseases related to Hairy Cell Leukemia:



Diseases related to Hairy Cell Leukemia

Symptoms & Phenotypes for Hairy Cell Leukemia

MGI Mouse Phenotypes related to Hairy Cell Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 IL2 IL2RA ITGAE ITGAX ADA ANXA1
2 digestive/alimentary MP:0005381 9.63 IL2 IL2RA ADA ANXA1 BRAF CCND1
3 immune system MP:0005387 9.32 CD5 IL2 IL2RA ITGAE ITGAX ADA

Drugs & Therapeutics for Hairy Cell Leukemia

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
3
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Sensipar 18 CINACALCET HYDROCHLORIDE Amgen March 2004
5
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
6
UroXatral 18 ALFUZOSIN HYDROCHLORIDE Sanofi-aventis June 2003
7
Valchlor 18 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
8
Zuplenz 18 ONDANSETRON Strativa Pharmaceuticals July 2010
9
Patanase 18 OLOPATADINE HYDROCHLORIDE Alcon April 2008
10
Xopenex 18 LEVALBUTEROL HYDROCHLORIDE Sepracor February 2002
11
Zyrtec 18 CETIRIZINE HYDROCHLORIDE Pfizer December 1995

Drugs for Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
3
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
4
Ofloxacin Approved Phase 3 82419-36-1 4583
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
6
Cladribine Approved, Investigational Phase 3,Phase 2,Phase 1 4291-63-8 20279
7
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
8
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
9
Dalteparin Approved Phase 3 9005-49-6
10
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
11
Ondansetron Approved Phase 3,Phase 2,Not Applicable 99614-02-5 4595
12
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
13
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
14
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Piperacillin Approved Phase 3 66258-76-2 43672
17
Tazobactam Approved Phase 3 89786-04-9 123630
18
Vancomycin Approved Phase 3 1404-90-6 441141 14969
19
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
20
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
22
Captopril Approved Phase 3 62571-86-2 44093
23
Palivizumab Approved, Investigational Phase 3 188039-54-5
24
Ribavirin Approved Phase 3 36791-04-5 37542
25
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
26
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
27
Acyclovir Approved Phase 3 59277-89-3 2022
28
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
29 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
30
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
31
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
32
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
33
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
34
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
35
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
36 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
37 Analgesics Phase 3,Not Applicable
38 Anesthetics Phase 3
39 Anesthetics, Dissociative Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
43 Excitatory Amino Acid Antagonists Phase 3
44 Excitatory Amino Acids Phase 3
45 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Cephalosporins Phase 3
50 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 219)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
4 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
5 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
6 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
7 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
8 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
9 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
10 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
11 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
12 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
15 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
16 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
19 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
20 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
21 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
22 Therapy Optimisation for the Treatment of Hairy Cell Leukemia Recruiting NCT02131753 Phase 2, Phase 3 Cladribine s.c. injection, HCL treatment
23 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Active, not recruiting NCT01829711 Phase 3 moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
24 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
25 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
26 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
27 Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab Completed NCT02157181 Phase 2 2CdA +/- Rituximab
28 A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Completed NCT00001567 Phase 2 Roferon-A
29 BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia Completed NCT00074048 Phase 2 BL22
30 Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy Completed NCT00003757 Phase 2
31 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
32 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
33 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
34 Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Completed NCT00005606 Phase 2
35 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
36 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
37 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
38 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
39 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
40 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
41 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
42 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
43 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
44 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
45 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
46 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
47 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
48 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
49 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
50 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus

Search NIH Clinical Center for Hairy Cell Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: leukemia, hairy cell

Genetic Tests for Hairy Cell Leukemia

Genetic tests related to Hairy Cell Leukemia:

# Genetic test Affiliating Genes
1 Hairy Cell Leukemia 29

Anatomical Context for Hairy Cell Leukemia

MalaCards organs/tissues related to Hairy Cell Leukemia:

41
Bone, Bone Marrow, B Cells, T Cells, Spleen, Lymph Node, Prostate

Publications for Hairy Cell Leukemia

Articles related to Hairy Cell Leukemia:

(show top 50) (show all 750)
# Title Authors Year
1
Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis. ( 29685423 )
2018
2
Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte-binding anti-CD antibody microarray. ( 29636954 )
2018
3
Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. ( 29606948 )
2018
4
Hairy cell leukemia presenting with progressive pericarditis and pleuritis. ( 29846761 )
2018
5
Schnitzler syndrome associated with hairy cell leukemia presenting with chronic urticaria and arthralgias. ( 29693079 )
2018
6
Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. ( 29955146 )
2018
7
Recent advances in understanding and managing hairy cell leukemia. ( 29770206 )
2018
8
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. ( 29487070 )
2018
9
Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands. ( 29382643 )
2018
10
Hairy Cell Leukemia with Unusual Presentation. ( 29678856 )
2018
11
<i>Listeria monocytogenes</i> Infection in Hairy Cell Leukemia: A Case Report and Literature Review. ( 29651349 )
2018
12
Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing. ( 29238890 )
2018
13
Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature. ( 29963523 )
2018
14
Androgen Therapy for Acute Myeloid and Hairy Cell Leukemia. ( 29362898 )
2018
15
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report. ( 29685167 )
2018
16
Update on hairy cell leukemia. ( 29742076 )
2018
17
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. ( 29118233 )
2017
18
Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. ( 29110361 )
2017
19
Immunohistochemical Detection of Hairy Cell Leukemia in Paraffin Sections: The Role of Pax5 and CD103 Double Staining to Improve Specificity and Sensitivity. ( 28418282 )
2017
20
Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. ( 28302693 )
2017
21
sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-I+ therapy. ( 28214980 )
2017
22
Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol. ( 28391438 )
2017
23
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. ( 29299182 )
2017
24
Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis. ( 28485619 )
2017
25
Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man. ( 28512405 )
2017
26
Hairy cell leukemia: a case report of atypical presentation without splenomegaly. ( 28698853 )
2017
27
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. ( 28918710 )
2017
28
Genomics of Hairy Cell Leukemia. ( 28297625 )
2017
29
Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience. ( 29199176 )
2017
30
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. ( 28801450 )
2017
31
Time to cure hairy cell leukemia. ( 28840848 )
2017
32
Morphologic Confounders and CD19 Negativity in a Case of Hairy Cell Leukemia. ( 28512562 )
2017
33
Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine. ( 29296733 )
2017
34
A rare breed: Wild-type braf and ighv expression in a 29 year old lady with classical hairy cell leukemia. ( 28275540 )
2017
35
Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience. ( 28747289 )
2017
36
A specific abnormal scattergram of peripheral blood leukocytes that may suggest hairy cell leukemia. ( 29220882 )
2017
37
Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy. ( 28596664 )
2017
38
MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab. ( 29285581 )
2017
39
An Unusual Giant Leg Ulcer as a Rare Presentation of Sweet's Syndrome in a Patient with Hairy Cell Leukemia Successfully Managed by Splenectomy. ( 28270371 )
2017
40
Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report. ( 29196889 )
2017
41
Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. ( 28778620 )
2017
42
An extremely rare case of concurrent<i>BRAF</i>V600E mutation driven hairy cell leukemia and melanoma: case report and review of literature. ( 29043205 )
2017
43
BRAF inhibition in hairy cell leukemia with low dose vemurafenib. ( 26941398 )
2016
44
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. ( 27903528 )
2016
45
Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With aA History of Hairy Cell Leukemia. ( 27117521 )
2016
46
BRAF inhibitor: targeted therapy in hairy cell leukemia. ( 27282942 )
2016
47
Hairy cell leukemia followed by polycythemia vera: report of the first case. ( 26941958 )
2016
48
Toxoplasmic Encephalitis with Untreated Hairy Cell Leukemia Variant. ( 27803415 )
2016
49
Hairy cell leukemia-variant without typical morphology and with Near-tetraploid DNA Content. ( 27997757 )
2016
50
CD27-positive hairy cell leukemia-Japanese variant. ( 26868143 )
2016

Variations for Hairy Cell Leukemia

Expression for Hairy Cell Leukemia

Search GEO for disease gene expression data for Hairy Cell Leukemia.

Pathways for Hairy Cell Leukemia

Pathways related to Hairy Cell Leukemia according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ANXA1 BRAF CCND1 CD22 IFNA1 IFNA2
2
Show member pathways
13.27 BRAF IFNA1 IFNA2 IL2 IL2RA IL3
3
Show member pathways
13.26 CCND1 IL2 IL2RA IL3 ITGAE ITGAX
4
Show member pathways
13.15 IFNA1 IFNA2 IL2 IL2RA IL3 ITGAX
5
Show member pathways
12.88 BRAF IL2 IL2RA IL3 ITGAE ITGAX
6
Show member pathways
12.8 CCND1 IFNA1 IFNA2 IL2 IL2RA IL3
7
Show member pathways
12.72 ANXA1 BRAF CCND1 IFNA1 IFNA2 IL2
8
Show member pathways
12.69 CCND1 IFNA1 IFNA2 IL2 IL2RA IL3
9
Show member pathways
12.62 CCND1 IFNA1 IFNA2 IL2 IL2RA
10 12.42 BRAF CCND1 IFNA1 IFNA2 IL2 IL2RA
11 12.4 IFNA1 IL2 IL2RA IL3
12
Show member pathways
12.33 BRAF IFNA1 IFNA2 IL2 IL3
13
Show member pathways
12.33 CCND1 IFNA1 IFNA2 IL2 IL2RA IL3
14 12 ANXA1 BRAF CCND1
15 12 CCND1 IL2RA ITGAE ITGAX
16
Show member pathways
11.99 IL2 IL2RA IL3
17 11.92 BRAF IFNA1 IFNA2
18
Show member pathways
11.88 BRAF IL2 IL2RA
19 11.86 ANXA1 CCND1 IL2
20 11.83 ANXA1 CCND1 ITGAX
21
Show member pathways
11.82 IL2 IL2RA IL3
22 11.69 CD22 CD5 IL2RA IL3
23 11.66 IL2 IL2RA ITGAE
24 11.66 IFNA1 IFNA2 IL2 IL2RA IL3
25
Show member pathways
11.61 IL2 IL2RA IL3
26 11.54 IFNA2 IL2 ITGAE ITGAX
27
Show member pathways
11.49 BRAF IL2 IL2RA
28 11.23 CD22 CD5 IFNA2 IL2 IL2RA IL3

GO Terms for Hairy Cell Leukemia

Cellular components related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 ADA ANXA1 FCRL5 IL2RA ITGAX
2 external side of plasma membrane GO:0009897 9.02 ADA CD5 IL2RA ITGAE ITGAX

Biological processes related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.92 ADA CD22 IL2 ITGAE ITGAX
2 regulation of signaling receptor activity GO:0010469 9.9 IFNA1 IFNA2 IL2 IL3
3 MAPK cascade GO:0000165 9.8 BRAF IL2 IL2RA IL3
4 adaptive immune response GO:0002250 9.76 ANXA1 IFNA1 IFNA2 IL2
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IFNA2 IL2 IL3
6 positive regulation of activated T cell proliferation GO:0042104 9.59 IL2 IL2RA
7 response to X-ray GO:0010165 9.58 ANXA1 CCND1
8 T cell activation involved in immune response GO:0002286 9.58 IFNA1 IFNA2
9 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.57 IFNA1 IFNA2
10 natural killer cell activation involved in immune response GO:0002323 9.56 IFNA1 IFNA2
11 regulation of regulatory T cell differentiation GO:0045589 9.55 IL2 IL2RA
12 regulation of T cell differentiation GO:0045580 9.54 ADA BRAF
13 positive regulation of T cell proliferation GO:0042102 9.54 ANXA1 IL2 IL2RA
14 interleukin-2-mediated signaling pathway GO:0038110 9.51 IL2 IL2RA
15 response to vitamin E GO:0033197 9.48 ADA CCND1
16 negative regulation of inflammatory response GO:0050728 9.46 ACP5 ADA IL2 IL2RA
17 alpha-beta T cell differentiation GO:0046632 9.4 ANXA1 BRAF
18 negative regulation of lymphocyte proliferation GO:0050672 9.32 IL2 IL2RA
19 regulation of T cell homeostatic proliferation GO:0046013 9.26 IL2 IL2RA
20 cytokine-mediated signaling pathway GO:0019221 9.23 ANXA1 CCND1 IFNA1 IFNA2 IL2 IL2RA
21 positive regulation of T cell differentiation GO:0045582 9.13 ADA IL2 IL2RA

Molecular functions related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 IL2 IL2RA IL3
3 cytokine activity GO:0005125 8.92 IFNA1 IFNA2 IL2 IL3

Sources for Hairy Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....